Description

Diseases of the musculoskeletal system affect 70% of the population over the age of 50 years.

Musculoskeletal diseases such as rheumatoid arthritis and polymyositis are characterized by chronic inflammation which is associated with the release of prostaglandins.

• Works by inhibiting the production of prostaglandins that cause inflammation and pain in the body. 
• Epidemiological studies have revealed the reduced risk of several cancer types and neurodegenerative diseases by prolonged use of NSAIDs.

• Diclofenac Sodium (NSAIDs)

• A phenylacetic acid derivative, non-selective NSAID hence, inhibits the production of both physiologic and inflammatory prostaglandins.

• Highly effective at therapeutic doses in the treatment of pain and physical disability in rheumatic diseases.

• Diclofenac is useful for short-term treatment of postoperative pain, acute musculoskeletal pain, and dysmenorrhea.

• Paracetamol (Analgesics and antipyretics)

• Acetaminophen (paracetamol) is a selective cyclooxygenase-2 inhibitor with weak anti-inflammatory effects.

• Superior overall gastrointestinal safety profile compared with NSAIDs.

• Demonstrated therapeutic efficacy in both acute and chronic pain.

Combination

• Paracetamol is active as a single agent and is additive or synergistic with NSAIDs and opioids, improving their efficacy and safety.

• A combination of paracetamol and an NSAID like Diclofenac Sodium may offer superior analgesic efficacy for treating acute postoperative pain compared with either drug alone.